Safety

Junshi Biosciences Announces Acceptance of Supplemental Application for Additional Indications of Adalimumab Injection

Retrieved on: 
Thursday, August 18, 2022 - 2:21am
Psoriasis, GLOBE, Death, EUA, Prevalence, Marketing, Patient, Ulcerative colitis, Glaucoma, National Medical Products Administration, Inflammation, Junshi, IBD, Autoimmunity, Macular edema, Social responsibility, Lilly, B cell, HKEX, NMPA, Safety, SSE, Juvenile idiopathic arthritis, Rheumatoid arthritis, Incidence, Rheumatism, Microbiology, Cancer, COVID-19, Severe acute respiratory syndrome coronavirus 2, Degenerative disease, FDA, Inflammatory bowel disease, Retinopathy, Cataract, UC, Ankylosing spondylitis, Bamlanivimab, Multifocal choroiditis and panuveitis, Quality of life, Company, Infection, TNF, Severe cognitive impairment, Macrophage, Bamlanivimab/etesevimab, Uveitis, Pharmaceutical industry, Vaccine, Chinese, Science

SHANGHAI, China, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the Company has received an Acceptance Notice issued by the National Medical Products Administration (“NMPA”). The supplemental application for additional indications of the company’s adalimumab injection (project code: UBP1211, trade name: 君迈康), including the treatment of Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, plaque psoriasis in children and Crohn’s disease in children, has been accepted.

Key Points: 
  • The supplemental application for additional indications of the companys adalimumab injection (project code: UBP1211, trade name: ), including the treatment of Crohns disease, uveitis, polyarticular juvenile idiopathic arthritis, plaque psoriasis in children and Crohns disease in children, has been accepted.
  • is jointly developed by Junshi Biosciences and Mabwell (Shanghai) Bioscience Co., Ltd.
  • In March 2022, its indications including rheumatoid arthritis, ankylosing spondylitis and psoriasis were approved by the NMPA.
  • Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc).

Hagens Berman: Class-Action Lawsuit Accuses Ford of Botching “Fix” Doled out for Defect Causing Vehicle Fires in Certain Hybrid Models

Retrieved on: 
Thursday, August 18, 2022 - 12:31am
Class Action Lawsuit, Professional Services, Legal, National Highway Traffic Safety Administration, Hand, Steve Berman (lawyer), Titanic, Escape, Failure, Trailblazer, Lists of action films, Group, History, Smoke, Douglas v. U.S. District Court ex rel Talk America, Fire, Review, MVP Baseball (series), Fraud, Safety, Maverick, District court, Lincoln, Ford Motor Company, Lincoln Corsair, News, Groundwater, Ford Maverick, Sport utility vehicle, Car rental, Road, Tobacco

If you purchased or leased a 2020-2022 Ford Escape, 2022 Ford Maverick or 2021-2022 Lincoln Corsair, contact Hagens Berman to find out more about this issue and your consumer rights against Ford.

Key Points: 
  • If you purchased or leased a 2020-2022 Ford Escape, 2022 Ford Maverick or 2021-2022 Lincoln Corsair, contact Hagens Berman to find out more about this issue and your consumer rights against Ford.
  • Ford admits that the Fire Defect Vehicles suffer from engine manufacturing issues that can cause engine failures involving engine block or oil pan breach.
  • But Fords fix is wholly silent as to this admittedly affected component, the lawsuit states.
  • Fords fix is essentially rearranging deck chairs on the Titanic, said Steve Berman, Hagens Berman co-founder and managing partner.

United States Steel Corporation, Big River Steel LLC and BRS Finance Corp. Commence Tender Offers to Purchase for Cash $300,000,000 Aggregate Principal Amount of Securities

Retrieved on: 
Wednesday, August 17, 2022 - 11:52pm
Other Manufacturing, Manufacturing, Steel, Settlement, J.P. Morgan & Co., U.S. Securities and Exchange Commission, Exercise, Expiration, Mini-tender offer, Goldman, Date, Tender offer, Wall Street, Sumathi Best Television Current Reporting Award, LLC, Security (finance), Credit Suisse, Attention, Compliance, Wells Fargo, U.S. Steel, Company, Iron, Safety, Personal Information Agent, Acceptance, Expiration date, Tender, Priority level, U. S. Steel Košice, s.r.o., Time, Annual report, Settlement date, Life insurance, Cryptocurrency, Central Europe

The Total Consideration includes the early tender premium for such series of Securities also set forth in the table above (the Early Tender Premium).

Key Points: 
  • The Total Consideration includes the early tender premium for such series of Securities also set forth in the table above (the Early Tender Premium).
  • Holders must validly tender and not subsequently validly withdraw their Securities at or prior to the Early Tender Date in order to be eligible to receive the Total Consideration for such Securities purchased in the Tender Offers.
  • The Offerors have retained Goldman, Sachs & Co. LLC, Credit Suisse Securities (USA) LLC, J.P. Morgan Securities LLC and Wells Fargo Securities, LLC to serve as Dealer Managers for the Tender Offers.
  • Holders of Securities must make their own decision as to whether to tender their Securities and, if so, the principal amount of such Securities to tender.

Shaklee, American Forests Celebrate 2 Million Trees Planted in North America

Retrieved on: 
Wednesday, August 17, 2022 - 11:00pm
Multimedia, Carbon, Climate change, CEO, Dream, Nobel Peace Prize, Yale College, American Forests, Yale Law School, Harvard University, Environment, Green Belt Movement, Midwest Universities Consortium for International Activities, Safety, Yale University, World Economic Forum, University council, Harvard Business School, Tree, Health, Forestry, Management, Science, Facebook, Shaklee, Instagram

PLEASANTON, Calif., Aug. 17, 2022 /PRNewswire/ -- Shaklee, a leading wellness company, today celebrates planting 2 million trees in North America. The effort is part of its Million Trees, Million Dream program in cooperation with American Forests, the oldest national nonprofit conservation organization in the United States.

Key Points: 
  • On the heels of the historic climate legislation, wellness and sustainability pioneer strengthens commitment to people, planet and purpose through its 'Million Trees, Million Dreams' program
    PLEASANTON, Calif., Aug. 17, 2022 /PRNewswire/ -- Shaklee , a leading wellness company, today celebrates planting 2 million trees in North America.
  • The effort is part of its Million Trees, Million Dream program in cooperation with American Forests , the oldest national nonprofit conservation organization in the United States.
  • Last year, Shaklee increased its commitment to the planet with a pledge to plant 10 million trees in 10 years.
  • For 2 million trees planted, approximately 96 million pounds of carbon dioxide will be eliminated from the atmosphere each year.1
    For more than 65 years, Shaklee has led the way in environmental stewardship.

Plus Therapeutics Awarded $17.6 Million from State of Texas

Retrieved on: 
Wednesday, August 17, 2022 - 10:46pm
Woman, U.S. Securities and Exchange Commission, Texas Legislature, Cancer prevention, Metastasis, LM, GLOBE, Food, Neoplasm, Diagnosis, Research institute, Cancer, Cancer Prevention and Research Institute of Texas, Research, Perception, Patient, Therapy, Company, Lone Star, Cohort, Program, Breast cancer, Radiation, Central nervous system, Safety, Nasdaq, Fast Track, Financial toxicity, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Data monitoring committee, PSTV, Organization, Pharmaceutical industry

AUSTIN, Texas, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that it was awarded a $17.6 million Product Development Research grant by the Cancer Prevention and Research Institute of Texas (CPRIT) to fund the continued development of the Company’s lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), for the treatment of patients with leptomeningeal metastases (LM).

Key Points: 
  • The Plus team is honored to receive this significant and esteemed award from CPRIT, said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics.
  • In the second quarter of 2022, the Company completed enrollment of Cohort 1 in the ReSPECT-LM Phase 1/2a dose escalation trial ( NCT05034497 ).
  • To date, CPRIT has awarded $2.9 billion in grants to Texas research institutions and organizations through its academic research, prevention and product development research programs.
  • Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases.

Most Watched Yacht Youtubers, NautiStyles, Announce The Purchase Of Their First Semi-Custom Bering 75 Explorer Yacht

Retrieved on: 
Wednesday, August 17, 2022 - 10:11pm
Interview, YouTube, Bering, Instagram, Safety, LOA, Social media, News, USCG, Shipbuilding

MIAMI, Aug. 17, 2022 /PRNewswire/ -- After three years of touring hundreds of yachts, YachtTubers Victoria Chalaya & Rico Stoll, the founders and hosts of NautiStyles, the most watched US-based yacht walk-through YouTube channel, with close to 300,000 subscribers and more than 4 million views per month, have chosen a Bering 75 as their next yacht! US-based Bering Yachts, manufacturers of semi-custom steel hull Explorer Yachts, with shipyard locations in Bulgaria and Turkey, are built for those who are not willing to compromise on safety, quality, and luxury. Over the coming year, viewers can join NautiStyles on their new YouTube channel, NautiGuys, as they document every step of designing and building their dream yacht.

Key Points: 
  • Over the coming year, viewers can join NautiStyles on their new YouTube channel, NautiGuys, as they document every step of designing and building their dream yacht.
  • NautiGuys is the first channel to take viewers behind the scenes of what it takes to build a long-range, real-deal steel Explorer Yacht.
  • The Bering 75 model features an LOA of 23.44 meters and displaces 160 metric tons with a whopping gross tonnage of 174 tons.
  • The Bering 75 offers an impressive 4,000+ nautical mile range with a cruising speed of nine knots and a top speed of 11 knots.

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Uber Technologies, Inc. (UBER)

Retrieved on: 
Wednesday, August 17, 2022 - 9:56pm
Disclosure, Risk, NYSE, GLOBE, Company, Uber, Complaint, Safety, District court, News, International Consortium of Investigative Journalists, Ridesharing company, Guardian

Investors who purchased or otherwise acquired shares of Uber should contact the Firm prior to the October 17, 2022 lead plaintiff motion deadline.

Key Points: 
  • Investors who purchased or otherwise acquired shares of Uber should contact the Firm prior to the October 17, 2022 lead plaintiff motion deadline.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq.
  • of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at tjmckenna@gme-law.com or gegleston@gme-law.com .

RECELL® System Data to be Presented at the Controversies and Conversations in Laser & Cosmetic Surgery Annual Meeting

Retrieved on: 
Wednesday, August 17, 2022 - 9:50pm
Transfer, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Dermatology, AVH, Industry, Forward-looking statement, GLOBE, Failure, Technology, Growth, Clinical trial, CA, Burn, Regenerative medicine, USE, ASX, Avita Medical, Patient, MHS, Adult, Skin, Safety, Evidence, NASDAQ, Epidermis, PMA, Autotransplantation, Controversy, Burns, PMDA, Solution, MD, Light, Contraindication, Food, Vitiligo, Health care, Pharmaceutical industry, Medical device

Following review by the FDA, we believe the RECELL System may well offer a welcome treatment option for patients seeking repigmentation for stable vitiligo lesions.

Key Points: 
  • Following review by the FDA, we believe the RECELL System may well offer a welcome treatment option for patients seeking repigmentation for stable vitiligo lesions.
  • AVITA Medical is currently completing a pivotal trial for the use of the RECELL System for treatment of stable vitiligo.
  • The vitiligo clinical trial aims to demonstrate safe and effective repigmentation when using the RECELL System in combination with phototherapy.
  • AVITA Medicals first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018.

Profire Energy to Present and Host Investor Meetings at the 13th Annual Midwest IDEAS Investor Conference on August 24th

Retrieved on: 
Wednesday, August 17, 2022 - 9:17pm
GLOBE, Profire Energy, Learning, Acheson, Engineering, Company, IDEAS, Midwestern United States, Safety, NASDAQ, Solution, Conference, Efficiency

The presentation will be webcast and may be accessed through the conference hosts main website: https://www.threepartadvisors.com/midwest .

Key Points: 
  • The presentation will be webcast and may be accessed through the conference hosts main website: https://www.threepartadvisors.com/midwest .
  • Qualified investors interested in attending or learning more about the IDEAS conferences should contact Steven Hooser at (214) 872-2710 or shooser@threepa.com.
  • Profire Energy is a technology company providing solutions that enhance the efficiency, safety, and reliability of industrial combustion appliances while mitigating potential environmental impacts related to the operation of these devices.
  • It has an experienced team of sales and service professionals that are strategically positioned across the United States and Canada.

Bath & Body Works Reports Second Quarter Sales and Earnings Results

Retrieved on: 
Wednesday, August 17, 2022 - 9:15pm
Paper, U.S. Securities and Exchange Commission, Interim, Lists of disasters, Industry, Name, NYSE, Legislation, GLOBE, Secrecy, Private Securities Litigation Reform Act, Growth, Share repurchase, BODY, Interbank, Security (finance), Environment, Annual report, Compliance, Theft, Income, Marketing, COVID-19, War, Bath & Body Works, Pandemic, Transport, Safety, Edmonton Transit Service, Forecasting, Privacy, Weather, Advertising, Printing, Information technology, Retail, Video game, Risk management, Management, Mobile phone, Audit, Renewable energy, Weapon, Rail transport, Financial adviser

COLUMBUS, Ohio, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Bath & Body Works, Inc. (NYSE: BBWI) today reported second quarter 2022 results.

Key Points: 
  • COLUMBUS, Ohio, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Bath & Body Works, Inc. (NYSE: BBWI) today reported second quarter 2022 results.
  • The company reported net sales of $1.618 billion for the second quarter ended July 30, 2022, a decrease of 5% compared to net sales of $1.704 billion for the second quarter ended July 31, 2021, but an increase of 45% compared to the second quarter of 2019.
  • The company reported earnings from continuing operations per diluted share of $0.52 for the second quarter ended July 30, 2022, compared to $0.77 for the quarter ended July 31, 2021.
  • Additional second quarter financial information, including management commentary, is currently available at www.BBWInc.com .Bath & Body Works, Inc.will conduct its second quarter earnings call at9:00 a.m.Eastern on Aug. 18.To listen, call 1.888.946.7609 (international dial-in number: 1.517.308.9411); conference ID 6362067.